Stryker (SYK - Free Report) reported $4.91 billion in revenue for the quarter ended September 2023, representing a year-over-year increase of 9.6%. EPS of $2.46 for the same period compares to $2.12 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $4.88 billion, representing a surprise of +0.59%. The company delivered an EPS surprise of +0.82%, with the consensus EPS estimate being $2.44.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Stryker performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- Orthopaedics and Spine- Knees- United States: $385 million versus $397.70 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +5.5% change.
- Geographic Revenue- International: $1.23 billion versus the three-analyst average estimate of $1.26 billion. The reported number represents a year-over-year change of +10%.
- Net Sales- Orthopaedics and Spine- Trauma and Extremities- United States: $550 million compared to the $533.65 million average estimate based on three analysts. The reported number represents a change of +11.3% year over year.
- Net Sales- Orthopaedics and Spine- Hips- United States: $231 million versus the three-analyst average estimate of $236.82 million. The reported number represents a year-over-year change of +2.7%.
- Net Sales- MedSurg and Neurotechnology: $2.86 billion versus the nine-analyst average estimate of $2.82 billion. The reported number represents a year-over-year change of +10.5%.
- Net Sales- Orthopaedics and Spine: $2.05 billion compared to the $2.06 billion average estimate based on eight analysts. The reported number represents a change of +8.4% year over year.
- Net Sales- Orthopaedics and Spine- Knees: $515 million compared to the $531.82 million average estimate based on seven analysts. The reported number represents a change of +7.1% year over year.
- Net Sales- MedSurg and Neurotechnology- Medical: $798 million versus the seven-analyst average estimate of $838.71 million. The reported number represents a year-over-year change of +4.3%.
- Net Sales- MedSurg and Neurotechnology- Endoscopy: $738 million compared to the $697.23 million average estimate based on seven analysts. The reported number represents a change of +25.1% year over year.
- Net Sales- Orthopaedics and Spine- Hips: $362 million compared to the $376.76 million average estimate based on seven analysts. The reported number represents a change of +4.3% year over year.
- Net Sales- Other Orthopaedics and Spine- Total: $130 million versus $116.50 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +17.1% change.
- Net Sales- Orthopaedics and Spine- Trauma and Extremities: $752 million compared to the $738.53 million average estimate based on seven analysts. The reported number represents a change of +11.9% year over year.
View all Key Company Metrics for Stryker here>>>Shares of Stryker have returned +5.1% over the past month versus the Zacks S&P 500 composite's +0.8% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.
Stryker (SYK - Free Report) reported $4.91 billion in revenue for the quarter ended September 2023, representing a year-over-year increase of 9.6%. EPS of $2.46 for the same period compares to $2.12 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $4.88 billion, representing a surprise of +0.59%. The company delivered an EPS surprise of +0.82%, with the consensus EPS estimate being $2.44.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Stryker performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- Orthopaedics and Spine- Knees- United States: $385 million versus $397.70 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +5.5% change.
- Geographic Revenue- International: $1.23 billion versus the three-analyst average estimate of $1.26 billion. The reported number represents a year-over-year change of +10%.
- Net Sales- Orthopaedics and Spine- Trauma and Extremities- United States: $550 million compared to the $533.65 million average estimate based on three analysts. The reported number represents a change of +11.3% year over year.
- Net Sales- Orthopaedics and Spine- Hips- United States: $231 million versus the three-analyst average estimate of $236.82 million. The reported number represents a year-over-year change of +2.7%.
- Net Sales- MedSurg and Neurotechnology: $2.86 billion versus the nine-analyst average estimate of $2.82 billion. The reported number represents a year-over-year change of +10.5%.
- Net Sales- Orthopaedics and Spine: $2.05 billion compared to the $2.06 billion average estimate based on eight analysts. The reported number represents a change of +8.4% year over year.
- Net Sales- Orthopaedics and Spine- Knees: $515 million compared to the $531.82 million average estimate based on seven analysts. The reported number represents a change of +7.1% year over year.
- Net Sales- MedSurg and Neurotechnology- Medical: $798 million versus the seven-analyst average estimate of $838.71 million. The reported number represents a year-over-year change of +4.3%.
- Net Sales- MedSurg and Neurotechnology- Endoscopy: $738 million compared to the $697.23 million average estimate based on seven analysts. The reported number represents a change of +25.1% year over year.
- Net Sales- Orthopaedics and Spine- Hips: $362 million compared to the $376.76 million average estimate based on seven analysts. The reported number represents a change of +4.3% year over year.
- Net Sales- Other Orthopaedics and Spine- Total: $130 million versus $116.50 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +17.1% change.
- Net Sales- Orthopaedics and Spine- Trauma and Extremities: $752 million compared to the $738.53 million average estimate based on seven analysts. The reported number represents a change of +11.9% year over year.
View all Key Company Metrics for Stryker here>>>Shares of Stryker have returned +5.1% over the past month versus the Zacks S&P 500 composite's +0.8% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.
Get the latest research report on SYK - FREE